TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex
- 1Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
- 2Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
- 3Pulmonary and Critical Care Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
- Dr E A Thiele, Carol and James Herscot Center for Tuberous Sclerosis Complex, 175 Cambridge Street, Suite 340, Boston, MA 02114, USA; ethiele{at}partners.org
- Received 1 December 2008
- Revised 17 February 2009
- Accepted 23 February 2009
- Published Online First 5 May 2009
Abstract
Background: Lymphangioleiomyomatosis (LAM) is a prominent finding in the setting of tuberous sclerosis complex (TSC).
Objective: The present study was designed to compare cystic lung changes consistent with LAM in patients with a TSC1 disease-causing mutation, TSC2 disease-causing mutation, or no mutation identified (NMI).
Methods and results: We conducted a retrospective review of the chest computed tomography (CT) of 45 female and 20 male patients with TSC and found cysts consistent with LAM in 22 (49%) women and two (10%) men. In the female population, changes consistent with LAM were observed in six of 15 (40%) patients with TSC1, 11 of 23 (48%) with TSC2, and five of seven (71%) with NMI. While the predominant size of cysts did not differ across these three groups, TSC2 women with LAM had a significantly greater number of cysts than did TSC1 patients (p = 0.010).
Conclusions: These findings suggest a higher rate of LAM in TSC1 than previously recognised, as well as a fundamental difference in CT presentation between TSC1 and TSC2.
Footnotes
-
Funding: This study was supported by the Carol and James Herscot Center for Tuberous Sclerosis Complex
-
Competing interests: None.
